美团又一次成为GLP-1减重药物的首发平台。7月3日,刚刚获批的减重创新药物玛仕度肽注射液(商品名:信尔美®)在美团医药健康旗下美团自营大药房首发上线。
对此,专家提醒:购买、用药仍需遵医嘱或在专业药师指导下进行。
据悉,这是继口服版司美格鲁肽和替尔泊肽之后,美团又一次承接GLP-1药物的全网独家首发,三款减重药物也将于美团平台内上演“三强争霸”。
凭借“产品+服务”的创新保障模式和大面积空运履约能力,美团成为GLP-1领域占领一定市场优势的医药电商。为了进一步保障GLP-1在运输过程中的品质,美团自营大药房近期也对运输装备进行了升级。目前采用的专属温控运输箱,不仅能够抵御外部高温辐射,也通过新型缓释型冰盒实现持久控温,全链路实现对药品的控温保质。
据了解,玛仕度肽可用于成人肥胖或超重患者的长期体重控制,这也是全球首个获批的GCG/GLP-1双受体激动减重药物。该药物此前在全球范围内开展了多项临床研究,有结果显示治疗20周减重降幅最高可达21%。降糖适应证预期也将在不久后获批。
据行业预测,2025年全球GLP-1药物市场规模将突破600亿美元,中国市场规模预计达45亿美元,年增长率超28%。
(文章来源:广州日报)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.